A powerful new agonist: flooding the system with growth hormone.

Abstract

Niemczyk et al. treated predialysis chronic kidney disease patients with a new growth hormone-releasing hormone agonist, AKL-0707, and noted important changes in body composition characterized by an increase in fat-free mass, a modest rise in bone mineral content, and a reduction in fat mass. These changes were accompanied by a reduction in both serum urea nitrogen and normalized protein nitrogen appearance rate, while dietary protein intake was unchanged. Importantly, there were no serious adverse events.

• Authors: Victoria S Lim
• Journal: Kidney international (Kidney Int) Vol. 77 Issue 5 Pg. 385-7 (Mar 2010) ISSN: 1523-1755 [Electronic] United States
• PMID: 20150938 (Publication Type: Comment, Journal Article)

Chemical References

• Human Growth Hormone
• Growth Hormone-Releasing Hormone

Topics

• Body Composition
• Bone Density
• Clinical Trials, Phase II as Topic
• Double-Blind Method
• Growth Hormone-Releasing Hormone (agonists, metabolism)
• Human Growth Hormone (adverse effects, metabolism)
• Humans
• Kidney Failure, Chronic (metabolism)
• Models, Biological
• Obesity (chemically induced)
• Randomized Controlled Trials as Topic